Gota de difícil manejo: a propósito de un caso

La gota es una artritis inflamatoria causada por la acumulación excesiva de cristales de urato monosódico a nivel tisular, predominando la afectación articular. Sus manifestaciones clínicas son variadas, condicionando usualmente un curso crónico de la enfermedad. El diagnóstico se realiza mediante el conjunto de hallazgos clínicos, bioquímicos e imagenológicos. El tratamiento se basa en medidas no farmacológicas y farmacológicas, dentro de los que se describen los inhibidores de xantina oxidasa y los uricosuricos. Se describe un caso de un paciente masculino con artritis gotosa de difícil manejo e hiperuricemia refractaria.

Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011; 63(10):3136-41.

https://doi.org/10.1002/art.30520

Qaseem A, Harris RP, Forciea MA, Physicians CGCotACo. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017; 166(1):58-68.

https://doi.org/10.7326/M16-0570

Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012; 64(10):1431-46.

https://doi.org/10.1002/acr.21772

Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016; 8(4):145-59.

https://doi.org/10.1177/1759720X16646703

Scirè CA, Rossi C, Punzi L, Genderini A, Borghi C, Grassi W. Change gout: how to deal with this "silently-developing killer" in everyday clinical practice. Curr Med Res Opin. 2018; 34(8):1411-7.

https://doi.org/10.1080/03007995.2018.1454896

Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015; 11(11):649-62.

https://doi.org/10.1038/nrrheum.2015.91

Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective - A review. J Adv Res. 2017; 8(5):495-511.

https://doi.org/10.1016/j.jare.2017.04.008

Juraschek SP, Miller ER, Gelber AC. Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken). 2011; 63(9):1295-306.

https://doi.org/10.1002/acr.20519

Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016; 388(10055):2039-52.

https://doi.org/10.1016/S0140-6736(16)00346-9

Ruoff G, Edwards NL. Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL? Postgrad Med. 2016;1 28( 7):706-15.

https://doi.org/10.1080/00325481.2016.1221732

Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006; 81(7):925-34.

https://doi.org/10.4065/81.7.925

Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015; 45(2):174-83.

https://doi.org/10.1016/j.semarthrit.2015.05.005

Frampton JE. Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. Drugs. 2015; 75(4):427-38.

https://doi.org/10.1007/s40265-015-0360-7

Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.

https://doi.org/10.1186/ar2978

Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59(11):1540-8.

https://doi.org/10.1002/art.24209

Wolff ML, Cruz JL, Vanderman AJ, Brown JN. The effect of angiotensin II receptor blockers on hyperuricemia. Ther Adv Chronic Dis. 2015; 6(6):339-46.

https://doi.org/10.1177/2040622315596119

Jung JY, Choi Y, Suh CH, Yoon D, Kim HA. Effect of fenofibrate on uric acid level in patients with gout. Sci Rep. 2018; 8(1):16767.

https://doi.org/10.1038/s41598-018-35175-z

Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, et al. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis Rheumatol. 2017; 69(1):203-12.

https://doi.org/10.1002/art.39840

Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017; 76(5):811-20.

https://doi.org/10.1136/annrheumdis-2016-209213

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol. 2017; 69(9):1903-13.

https://doi.org/10.1002/art.40159

Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011; 306(7):711-20.

https://doi.org/10.1001/jama.2011.1169

Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014; 18(6):876-84.

https://doi.org/10.1007/s10157-014-0935-8

Becker MA, Hollister AS, Terkeltaub R, Waugh A, Flynt A, Fitz-Patrick D, et al. FRI0367 BCX4208 added to allopurinol increases response rates in patients with GOUT who fail to reach goal range serum uric acid on allopurinol alone: A randomized, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. 2013; 71(Suppl 3):438.

https://doi.org/10.1136/annrheumdis-2012-eular.2824

Gallelli L. Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties. Drug Des Devel Ther. 2019; 13:3425-37.

https://doi.org/10.2147/DDDT.S207720

Du Y, Song Y, Zhang L, Zhang M, Fu F. Combined treatment with low dose prednisone and escin improves the anti-arthritic effect in experimental arthritis. Int Immunopharmacol. 2016; 31:257-65.

https://doi.org/10.1016/j.intimp.2016.01.006

Zhang L, Huang Y, Wu C, Du Y, Li P, Wang M, et al. Network Pharmacology Based Research on the Combination Mechanism Between Escin and Low Dose Glucocorticoids in Anti-rheumatoid Arthritis. Front Pharmacol. 2019; 10:280.

https://doi.org/10.3389/fphar.2019.00280

hiperuricemia
gota
alopurinol
febuxostat